Moore M, Hughes L A
Br J Cancer Suppl. 1973 Aug;1:175-84.
In a comparative study, sera from patients with connective tissue tumours, various carcinomata and from individuals without malignancy were evaluated by indirect immunofluorescence (IF) for antibodies reactive with apparently specific antigens shared by sarcoma derived tissue culture cell lines; for antibodies by IF to 2 tissue autoantigens (nuclear antigen and smooth muscle antigen) on rat liver substrate; and for HL-A antibodies by microcytotoxicity against a panel of 22 lymphocytes. Antibodies reactive with 11/16 cell lines originating from sarcomata were detected in 36% of all sarcoma sera tested, 12% carcinoma sera and 9% sera from controls. The incidence of antisarcoma antibody (ASA) was higher in the sera of sarcoma patients whose disease was in the primary phase (53%) compared with those in whom disease was advanced. A lower incidence (8%) of antibodies to nuclear antigen was detected in the sera of sarcoma patients compared with carcinoma patients (22%) and controls (23%), but the incidence of smooth muscle antibodies (SMA) was higher (45%) compared with carcinomata and controls (36% and 35% respectively). HL-A antibodies were present in 13% sarcoma sera, 36% carcinoma sera and 33% control sera. Evidence is presented to show that the various antibodies are distinct and that those reacting with sarcoma derived cell lines may be tumour associated antibodies possibly related to a virus specified antigen.
在一项比较研究中，通过间接免疫荧光法（IF）对结缔组织肿瘤患者、各种癌症患者以及无恶性肿瘤个体的血清进行了评估，以检测与肉瘤衍生组织培养细胞系共有的明显特异性抗原发生反应的抗体；通过IF检测大鼠肝基质上2种组织自身抗原（核抗原和平滑肌抗原）的抗体；并通过对一组22种淋巴细胞的微量细胞毒性检测HL-A抗体。在所有检测的肉瘤血清中，36%检测到与源自肉瘤的11/16种细胞系发生反应的抗体，癌血清中为12%，对照血清中为9%。与疾病晚期的肉瘤患者相比，处于疾病早期的肉瘤患者血清中抗肉瘤抗体（ASA）的发生率更高（53%）。与癌症患者（22%）和对照（23%）相比，肉瘤患者血清中核抗原抗体的发生率较低（8%），但平滑肌抗体（SMA）的发生率较高（45%），而癌症患者和对照的发生率分别为36%和35%。HL-A抗体在13%的肉瘤血清、36%的癌血清和33%的对照血清中存在。有证据表明，各种抗体是不同的，与肉瘤衍生细胞系发生反应的抗体可能是肿瘤相关抗体，可能与病毒特异性抗原有关。
